Drug Approval | December 13, 2023
FDA and EMA accept Marstacimab regulatory submissions for the treatment of Hemophilia A and B
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
_256_275.jpg)